- Home
- CNTY vs ELOX Comparison
CNTY vs ELOX Comparison
Compare CNTY & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTY | ELOX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 43.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTY | ELOX |
|---|---|---|
| Price | $1.27 | $12.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 64.5K | 40.1K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.23 | $10.00 |
| 52 Week High | $2.85 | $15.00 |
Technical Indicators
Market Signals| Indicator | CNTY | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 39.60 |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.47 | N/A |
| Average True Range (ATR) | 0.06 | 2.37 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 14.02 | 50.00 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.